Klybeck Life Sciences SA, headquartered in Dammam, Saudi Arabia, is a prominent manufacturer and exporter of veterinary vaccines, pharmaceuticals, and diagnostic solutions. With a strong regional and international presence, Klybeck is committed to advancing animal health through innovation, research-driven product development, and robust biosecurity practices. The company plays a crucial role in safeguarding the livestock, poultry, aquaculture, and pet industries across the Gulf region and beyond.
Core Business
Klybeck Life Sciences is focused on developing and delivering cutting-edge veterinary biologics, therapeutics, and feed additives. The company's core operations integrate vaccine production, pharmaceutical formulation, and veterinary diagnostics, providing comprehensive animal health solutions underpinned by high-quality manufacturing and scientific excellence.
Product and Service Offerings
1. Veterinary Vaccines
- Poultry Vaccines: Live and inactivated vaccines targeting ND, IB, IBD, and AI strains
- Livestock Vaccines: For cattle, sheep, goats — including FMD, brucellosis, and clostridial diseases
- Aquaculture Vaccines: Bacterial and viral control for fish and shrimp health
- Companion Animal Vaccines: For canine distemper, parvovirus, rabies, and feline diseases
2. Pharmaceuticals
- Injectables: Antibiotics like Florbeck (florfenicol), Iverbeck (ivermectin), and others
- Oral Solutions: Broad-spectrum antimicrobials and supportive therapies
- Powders: Electrolytes, antipyretics, and combination antibiotic treatments
3. Feed Additives
- Probiotics and Prebiotics: To improve gut flora and digestion
- Vitamin-Mineral Blends: Species-specific premixes to support immunity and growth
- Anti-stress and Performance Boosters: For intensive production cycles
4. Diagnostic Services
- Field Disease Surveillance: Sample collection and laboratory analysis
- Strain Isolation: Custom vaccine development based on prevalent pathogens
- Post-Vaccination Monitoring: Efficacy studies and serological evaluations
Specialization and Unique Selling Proposition (USP)
Klybeck’s strength lies in:
- In-house vaccine R&D and manufacturing with state-of-the-art BSL labs
- Region-specific vaccine formulations for GCC and African climates
- GMP and ISO-certified production facilities
- Rapid response diagnostics to emerging disease threats
Their customized vaccines have improved flock immunity and lowered mortality rates in large-scale poultry farms by 30–40%, as observed in recent field trials across Saudi Arabia and Oman.
Financial Performance
As a privately held firm:
- Estimated Annual Revenue (2023): $30M–$40M
- R&D Investment: Over 10% of annual revenue directed toward new antigen development
- Production Capacity: 100 million vaccine doses annually
Shipment and Export Data
Data from trade platforms and internal distribution logs indicate:
- Annual Shipments (2023): Over 300 international consignments
- Export Destinations: UAE, Egypt, Iraq, Nigeria, Pakistan, Bangladesh
- Popular Products: Poultry vaccine lines, Iverbeck injection, probiotic blends
Target Market
Klybeck serves:
- Commercial poultry and livestock integrators
- Veterinary clinics and pharmacies
- Feed manufacturers and aquaculture firms
- Ministries of Agriculture and veterinary institutions
Capabilities
- Full-cycle vaccine development from strain selection to packaging
- Modular GMP-compliant manufacturing units
- Cold chain distribution and technical support
- On-site and remote diagnostic support and training
Certifications and Compliance
- GMP Certified by the Saudi Food and Drug Authority (SFDA)
- ISO 9001:2015 for Quality Management Systems
- Compliant with OIE and WHO guidelines
- Halal Certified products available for regional markets
Customer Testimonials
Clients report a significant decline in mortality and improved performance indices using Klybeck’s customized vaccination protocols. A poultry operation in Egypt reported a 15% improvement in average daily weight gain and reduced culling rates by 25% after implementing Klybeck’s vaccine and feed additive programs.
Major Achievements
- Developed one of the first thermostable ND vaccines for the Middle East
- Partnered with veterinary schools for diagnostic training and field studies
- Named a top veterinary exporter by the Saudi Export Development Authority
- Expanded into aquaculture vaccine production in 2022
Klybeck Life Sciences SA continues to lead in regional animal health innovation by delivering effective, science-based solutions tailored to the needs of modern animal producers.
